Category: San Jose BioCenter
Date: March 25, 2010
Time: 3:00PM-6:30PM
Venue: Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road, Menlo Park CA 94025-1015
Registration Cost: from $0 to $70
Effectively raising capital is crucial for any company. Sufficient capital helps ensuring R&D, Due Diligence, Legal and Accounting services, Marketing, and improves hiring potential. In this session, a panel of VCs and CEOs will deliver the tips and tricks to realizing a successful financing process.
Questions that will be raised include: • What are the steps to prepare for a financing round? • What are the strategies for attracting, securing and structuring financing deals? • Is there a valuation best practice for an emerging company in this complex environment? • When to start your financing round, and when not to?
Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception. | Registration fee: from $0 to $70 | 3:00-6:30 | @ Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road, Building 1100, Menlo Park CA 94025-1015
Now, more than ever, start-ups can use all the help they can get. The San Jose BioCenter will provide your biotech or cleantech company with support for fundraising, business development, legal, lab support, HR and payroll activities, as well as, provide you with access to our $15 million dollar state-of-the-art laboratory facilities and shared equipment.
“In just 5 years San Jose BioCenter companies have raised over $1 Billion in deals and financing.” -Melinda Richter, Executive Director, San Jose BioCenter
Our mission is to provide life science and cleantech companies with the infrastructure, resources, networks and expertise they need to develop and commercialize their technology. The San Jose BioCenter was awarded the National Business Incubator Association (NBIA) International Incubator of the year award for 2009 because of our exceptional resources, programs and client success rate. After 1.5 years at the San Jose BioCenter, Tacere Pharmaceuticals inked a $145m development deal with Pfizer for its preclinical hepatitis C drug:
